Edith Cowan University

Research Online
Research outputs 2022 to 2026
12-1-2022

Genetic variants within NOGGIN, COL1A1, COL5A1, and IGF2 are
associated with musculoskeletal injuries in elite male Australian
football league players: A preliminary study
Ysabel Jacob
Edith Cowan University

Ryan S. Anderton
Jodie L. Cochrane Wilkie
Edith Cowan University, j.wilkie@ecu.edu.au

Brent Rogalski
Simon M. Laws
Edith Cowan University, s.laws@ecu.edu.au

See next page for additional authors

Follow this and additional works at: https://ro.ecu.edu.au/ecuworks2022-2026
Part of the Sports Sciences Commons
10.1186/s40798-022-00522-y
Jacob, Y., Anderton, R. S., Cochrane Wilkie, J. L., Rogalski, B., Laws, S. M., Jones, A., ... & Hart, N. H. (2022). Genetic
variants within NOGGIN, COL1A1, COL5A1, and IGF2 are associated with musculoskeletal injuries in elite male
Australian football league players: A preliminary study. Sports Medicine-Open, 8, Article 126. https://doi.org/
10.1186/s40798-022-00522-y
This Journal Article is posted at Research Online.
https://ro.ecu.edu.au/ecuworks2022-2026/1383

Authors
Ysabel Jacob, Ryan S. Anderton, Jodie L. Cochrane Wilkie, Brent Rogalski, Simon M. Laws, Anthony Jones,
Tania Spiteri, Dana Hince, and Nicolas H. Hart

This journal article is available at Research Online: https://ro.ecu.edu.au/ecuworks2022-2026/1383

(2022) 8:126
Jacob et al. Sports Medicine - Open
https://doi.org/10.1186/s40798-022-00522-y

ORIGINAL RESEARCH ARTICLE

Open Access

Genetic Variants within NOGGIN,
COL1A1, COL5A1, and IGF2 are Associated
with Musculoskeletal Injuries in Elite
Male Australian Football League Players:
A Preliminary Study
Ysabel Jacob1, Ryan S. Anderton2,3*, Jodie L. Cochrane Wilkie1,4, Brent Rogalski5, Simon M. Laws6,7,8,
Anthony Jones5, Tania Spiteri1, Dana Hince2 and Nicolas H. Hart1,2,4,9,10*   

Abstract
Introduction: Australian Football is a dynamic team sport that requires many athletic traits to succeed. Due to
this combination of traits, as well as technical skill and physicality, there are many types of injuries that could occur.
Injuries are not only a hindrance to the individual player, but to the team as a whole. Many strength and conditioning
personnel strive to minimise injuries to players to accomplish team success.
Purpose: To investigate whether selected polymorphisms have an association with injury occurrence in elite male
Australian Football players.
Methods: Using DNA obtained from 46 elite male players, we investigated the associations of injury-related polymorphisms across multiple genes (ACTN3, CCL2, COL1A1, COL5A1, COL12A1, EMILIN1, IGF2, NOGGIN, SMAD6) with injury
incidence, severity, type (contact and non-contact), and tissue (muscle, bone, tendon, ligament) over 7 years in one
Australian Football League team.
Results: A significant association was observed between the rs1372857 variant in NOGGIN (p = 0.023) and the number of total muscle injuries, with carriers of the GG genotype having a higher estimated number of injuries, and moderate, or combined moderate and high severity rated total muscle injuries. The COL5A1 rs12722TT genotype also had
a significant association (p = 0.028) with the number of total muscle injuries. The COL5A1 variant also had a significant
association with contact bone injuries (p = 0.030), with a significant association being found with moderate rated injuries. The IGF2 rs3213221-CC variant was significantly associated with a higher estimated number of contact tendon
injuries per game (p = 0.028), while a higher estimated number of total ligament (p = 0.019) and non-contact ligament (p = 0.002) injuries per game were significantly associated with carriage of the COL1A1 rs1800012-TT genotype.
Conclusions: Our preliminary study is the first to examine associations between genetic variants and injury in Australian Football. NOGGIN rs1372857-GG, COL5A1 rs12722-TT, IGF2 rs3213221-CC, and COL1A1 rs1800012-TT genotypes
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held various associations with muscle-, bone-, tendon- and ligament-related injuries of differing severities. To further
increase our understanding of these, and other, genetic variant associations with injury, competition-wide AFL studies
that use more players and a larger array of gene candidates is essential.
Keywords: Injury, Muscle, Tendon, Ligament, Bone, Contact, Non-contact, Genetics, Genes

Key Points
• In this select cohort of elite Australian Football players, those with the rs1372857-NOGGIN GG or
COL5A1 rs12722-TT genotype had a higher estimated number of total muscle-related injuries per
game. However, those with the NOGGIN rs1372857GG genotype also had a higher estimated number of
moderate-to-high severity rated injuries.
• The IGF2 rs3213221-CC genotype had a higher estimated number of contact tendon injuries per game,
and a higher number of low severity rated injuries.
• The rs1800012-TT genotype of COL1A1 had a higher
number of ligament-related injuries per game, with
significant associations seen between the genotype
and low severity rated injuries.
• The COL5A1 rs12722-TT genotype had a higher
number of contact bone injuries per game, and a
higher number of moderate severity rated injuries.

Introduction
Australian Football (AF) is a unique endurance-based
team sport interspersed with many high-intensity efforts
across a match [1–4]. In the elite competition, the Australian Football League (AFL), players regularly run over
13-kms per match over a 120-min period [5]. Players
continuously perform at an intense physical level due
to the dynamic nature of the sport which requires players to accelerate and decelerate, change direction, and
explosively jump repeatedly, while also performing sport
specific skills such as kicking, handballing, marking, and
tackling [6–10]. Due to the demands of the sport, injuries
occur frequently with the most common injuries including hamstring strains, anterior cruciate ligament (ACL)
ruptures, glenohumeral dislocations, leg and foot fractures (i.e. mainly stress fractures), and ankle joint injuries
[11]. To be successful, AFL teams not only need talented
athletes, but also lower injury rates to optimise player
availability for team selection [12], as greater team continuity allows less disruption of athlete personnel during a season, which can lead to better team consistency
and success [12]. Despite concerted efforts from strength
and conditioning coaches, and medical staff, there is
still an unknown combination of extrinsic and intrinsic

mechanisms that may affect an athlete’s rate of injury and
rate of recovery from injury, including genetic factors
[13–15].
The expression of certain genes influences various
physical athletic qualities such as body composition,
muscle stiffness, elasticity and strength, and response to
exercise-induced muscle damage [16–18]. Single nucleotide polymorphisms (SNPs) are naturally occurring variances in the human genome at a specific position, where
an individual may have a pair of the same DNA bases
(homozygous) or two different DNA bases (heterozygous) [19]. These polymorphisms could have no effect or
could be beneficial or deleterious to the individual [19].
SNPs can have an effect on musculoskeletal formation,
structure, repair, blood flow and metabolism [20–22],
influencing muscles, tendons, and ligaments [23]. The
presence of SNPs in different genes has been shown to
be related to musculoskeletal injury risk (alpha-actinin-3
[ACTN3] [24]; collagen type I alpha 1 [COL1A1] [25]),
musculoskeletal injury occurrence (collagen type V alpha
1 [COL5A1]) [14]), muscle injury severity (COL5A1;
insulin-like growth factor-2 [IGF2]; chemokine CC
motif ligand-2 [CCL2]) [26]), muscular strength (CCL2
[23]), an influence on muscle function (COL5A1 [27]),
increased risk of ACL injury (COL1A1; and collagen type
XII alpha 1 [COL12A1] [28, 29]), ligament injury severity (elastin microfibril interface 1 [EMILIN1] [26]), bone
mineral density (NOGGIN; and SMAD Family Member
6 [SMAD6] [30–32]), and injury recovery time (IGF2;
CCL2 [26]).
SNPs in the COL1A1, COL5A1, and COL12A1 genes
have all been reported to affect the production of their
associated collagen types. COL1A1 affects cell adhesion
and differentiation [33], COL5A1 is a part of the extracellular matrix and can influence the production of type V
collagen by altering mRNA stability [34], and COL12A1
is the link between fibrils and its mutations [35]. ACTN3
influences skeletal muscle formation as it forms the part
of the fibres responsible for rapid and forceful contractions [36]. IGF2 regulates cell proliferation, growth,
migration, differentiation, and survival via its protein
hormone [37]. CCL2 can recruit monocytes, memory
T cells, and dendritic cells as part of the CC chemokine
superfamily responsible for chemotactic activity and
increases in calcium influx [38]. EMILIN1 regulates
systemic blood pressure, as well as being part of the
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extracellular matrix [39–41]. NOGGIN is an extracellular
antagonist of the bone morphogenetic proteins (BMPs)
that regulate heart development via complex morphogenetic processes [42]. SMAD6 affects its protein which
is an intracellular mediator of signalling caused by BMPs
[43].
Genetic variants in multiple genes have been associated with injuries in clinical [25, 44, 45] and athletic [44,
46–48] populations. Within AF, team success relies on
many factors such as talent, skill, and fitness; however,
lower injury rates are also important, as injuries can keep
players from playing for a period of time or to the best
of their ability, and therefore, understanding potential
links to injury, such as genetics, is important. Research
has focussed on mechanisms of injury, for example, type
of technique, loading, muscle strength, timing of muscle
activation, previous injury history, age and fatigue [49–
51], and external factors, such as ground contact forces
and ground–shoe friction [11, 49], causing injury in AF.
However, the association between genetic variants and
injuries in AF has not been investigated. Accordingly, the
purpose of this study is to investigate whether the previously researched candidate polymorphism has an association with injury occurrence in an elite AFL playing
squad. We hypothesise that there will be a genetic influence on injury occurrence for at least one of the candidate polymorphisms.

Materials and Methods
Study Design

A prospective longitudinal cohort study was conducted
across seven consecutive seasons (2011 to 2017) used to
investigate the association of injury-related SNPs, in nine
genes (ACTN3, CCL2, COL1A1, COL5A1, COL12A1,
EMILIN1, IGF2, NOGGIN, and SMAD6), in a population
of professional, elite AF players to explore possible relationships between candidate SNPs and injury outcomes
(incidence [total, contact, non-contact] and severity [low,
moderate, high]) relating to muscle, tendon, ligament,
and bone. Estimated numbers of injuries per genotype
for each genetic variant are reported to provide easyto-interpret presentation of data for use by strength and
conditioning coaches.
Participants

Forty-six (n = 46) elite male AF players were recruited
from one AFL team to participate in the study, as previously described [52, 53]. For each in-season round, 22 to
23 players were selected to play in the AFL competition,
with the remaining 24 to 25 playing in the state competition for that given round (WAFL; Western Australian
Football League). Anonymity was ensured by assigning
players with a randomised, non-identifiable code. All
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participants provided written informed consent after
being provided with information letters outlining the
purpose of the study and potential benefits and risks.
All data collection and management procedures conformed to the Declaration of Helsinki (World Medical
Association) with ethics approved by the Edith Cowan
University Human Research and Ethics Committee (ID:
2019-00181-JACOB).
Injury Data Collection

Data were collected from medical and injury reports provided by the AFL club, recorded by their medical professionals, including doctors, physiotherapists, and strength
and conditioning personnel. Injuries were diagnosed
with a description of location and categorised as noncontact (i.e. intrinsic injuries that are acute, chronic, or
overuse injuries stemming from the athlete themselves)
or contact (i.e. extrinsic injuries that are acute collision
or contact injuries stemming from external forces). Club
medical staff provided each injury with a severity rating that is based on the number of training sessions and
games that elapsed from the date of injury to the date of
the player’s return to full participation in team training
with availability for match selection. Specifically, severity
was graded as low (i.e. training is modified or less than
1 week of training is missed, with no games missed),
moderate (i.e. 1–2 weeks of training missed, or unavailable for 1 to 2 games), or high (i.e. 3 or more weeks of
training missed, or unavailable for 3 or more games) as
an internal club-determined metric. All injuries were
then placed into a sub-category: bursitis; concussion;
contusion/bruise/haematoma; dislocation/subluxation;
fracture; lesion of meniscus, cartilage or disc; muscle
strain/tear/rupture/cramps; other bone injuries; other
injuries; sprain/ligament injury; joint instability; tendinopathy; or tendon injury/rupture. In our study, injuries that could be categorised into the broad categories
of (1) muscle (including muscle strain/tear/rupture/
cramps), (2) tendon (tendinopathy, and tendon injury/
rupture), (3) ligament (including sprain/ligament injury,
and joint instability), and (4) bone (including fracture,
and other bone injuries) were used. Data were collected
over 7 consecutive seasons (2011 to 2017). Injuries
occurring in training sessions or matches during the preseason (between 17 and 21 weeks depending on the year
and season over the Australian summer) and in-season
(between 23 and 27 weeks depending on the year and
season over the Australian winter with the inclusion of a
final series when applicable) were included. Players who
were injury-free in-season were either selected to play
in the national AFL competition or played in the state
WAFL competition. Due to the professional nature of the
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team and club, all players undertook a similar volume of
training when not injured.
Sample Collection and DNA Analysis

Buccal saliva samples were collected via mouth swabs
with participants instructed to brush the edge of a soft
tip swab along the insides of their cheek and gums for
30 s [52–54]. Samples were collected before a pre-season
training session and players were asked not to consume
coffee, alcohol, or food for two hours prior to saliva collection. Collected samples were labelled with a numeric
code for de-identification and were sent to the Australian
Genome Research Facility (AGRF; Brisbane, QLD, Australia; NATA 17025) for DNA extraction and genotyping using Agena Bioscience MassARRAY system (AGRF;
Brisbane, QLD, Australia). Genetic variants examined
were within the following genes: ACTN3 (rs1815739),
CCL2 (rs2857656), COL1A1 (rs1800012), COL5A1
(rs12722), COL12A1 (rs970547), EMILIN1 (rs2289360),
IGF2 (rs3213221), NOGGIN (rs1372857), SMAD6
(rs2053423), with all genotypes being within Hardy–
Weinberg equilibrium (HWE), as previously reported
[52].
Statistical Analysis

Data were statistically analysed using IBM-SPSS V.24
(Armonk, NY, USA) and Stata/BE v17 (StataCorp LLC,

Collage Station, TX, USA). A negative binomial distribution model was used to assess the relationship between
the total number of injuries per injury category (muscle,
tendon, ligament, and bone) and the genotypes of each
of the candidate genes. Each injury category was analysed
in total and via non-contact (i.e. intrinsic), and contact
(i.e. extrinsic) injury mechanism. The number of games
played was included as the offset variable to account for
differences in exposure to the risk of injury. Genotype
was considered a continuous variable to test for the linear trend in the association. Significant association with
a particular gene was followed up with separate models
to determine if there was an association between the
number of injuries within each injury category and their
severity (low, moderate, high, and a combination group
of moderate and high). These results are reported as incident rate ratios (IRRs) and estimated number of injuries
with 95% confidence intervals (95% CI). A significant
nominal p value of < 0.05 was employed.

Results
Longitudinal team descriptive results are presented
in Table 1, with genotype frequencies presented in
Table 2. The average number of injuries for each variant
per season is presented in Table 3 for muscle, tendon,
ligament, and bone-related injuries. Over the seven seasons, 992 incidents of injury were included, of which 351

Table 1 Descriptive statistics and mean player injuries for each season
AFL season
Variable

Season 1
(n = 46)

Season 2
(n = 40)

Season 3
(n = 29)

Season 4
(n = 25)

Season 5
(n = 21)

Season 6
(n = 18)

Season 7
(n = 15)

Age (Years)

24.94 (4.26)

24.20 (4.02)

23.90 (3.21)

23.60 (2.87)

23.38 (2.42)

22.50 (2.50)

21.93 (2.38)

Active weeks

35.23 (6.25)

35.73 (6.02)

41.45 (5.42)

36.60 (3.43)

35.19 (5.38)

37.28 (5.85)

41.20 (3.92)

Games played

17.45 (45)

18.78 (2.92)

20.03 (6.17)

18.60 (3.43)

17.57 (4.50)

19.28 (5.85)

20.73 (3.97)

Games lost

4.62 (6.72)

1.60 (2.92)

4.31 (6.93)

2.56 (3.56)

4.62 (4.58)

3.83 (6.29)

3.40 (4.38)

All Injuries

1.85 (1.61)

2.14 (3.35)

1.61 (1.37)

1.78 (1.19)

2.20 (1.56)

1.57 (1.16)

1.50 (1.15)

Muscle

3.40 (1.80)

2.08 (1.00)

2.06 (1.65)

1.91 (0.85)

3.05 (1.60)

1.72 (0.72)

1.82 (1.06)

Tendon

0.67 (0.47)

2.33 (1.25)

1.13 (0.33)

1.14 (0.35)

2.00 (1.41)

1.45 (0.66)

1.08 (0.28)

Ligament

1.26 (1.31)

1.65 (1.56)

1.90 (1.60)

2.08 (1.62)

1.48 (1.43)

1.56 (1.54)

1.27 (1.12)

Bone

0.62 (1.02)

0.40 (0.58)

0.83 (1.05)

0.68 (0.79)

0.48 (0.73)

0.39 (0.49)

0.53 (0.72)

2.12 (1.78)

1.50 (0.78)

1.58 (1.34)

1.50 (0.76)

2.29 (1.35)

1.35 (0.58)

1.54 (0.93)

Muscle

2.70 (2.10)

1.67 (0.62)

1.94 (1.65)

1.75 (0.77)

2.70 (1.45)

1.62 (0.72)

1.75 (1.00)

Tendon

2.00 (0.00)

2.00 (1.41)

1.00 (0.00)

1.29 (0.45)

2.20 (1.17)

1.18 (0.39)

1.09 (0.29)

Ligament

1.00 (0.00)

1.00 (0.00)

1.50 (0.50)

1.46 (0.93)

1.50 (0.71)

1.21 (0.41)

1.07 (0.26)

Bone

1.50 (0.50)

1.00 (0.00)

1.00 (0.00)

1.13 (0.33)

2.13 (1.27)

1.13 (0.33)

2.13 (1.27)

1.39 (0.59)

1.67 (1.05)

1.55 (0.74)

1.35 (0.62)

1.65 (0.90)

1.59 (0.93)

1.55 (0.76)

Muscle

1.00 (0.00)

1.33 (0.47)

1.00 (0.00)

1.00 (0.00)

1.50 (0.50)

1.33 (0.47)

0.00 (0.00)

Tendon

0.00 (0.00)

0.00 (0.00)

1.00 (0.00)

1.00 (0.00)

1.00 (0.00)

1.00 (0.00)

1.00 (0.00)

Ligament

1.67 (0.67)

1.92 (1.19)

1.77 (0.80)

1.41 (0.60)

1.95 (0.97)

1.82 (1.03)

1.60 (0.80)

Bone

1.25 (0.43)

1.00 (0.00)

1.25 (0.43)

1.40 (0.80)

1.00 (0.00)

1.00 (0.00)

1.40 (0.49)

Non-Contact Injuries

Contact Injuries
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Table 2 Player genotype and allele distribution of candidate
variants
n (%)
COL5A1 (rs1800012)

Table 2 (continued)
n (%)
COL12A1 (rs970547)
GG

1 (2.1)

CC

8 (17.0)

AG

13 (27.7)

CT

23 (48.9)

AA

33 (70.2)

TT

16 (34.0)

G

15 (16.0)

C

39 (41.5)

A

79 (84.0)

T

55 (58.5)

NOGGIN (rs1372857)
GG

9 (19.1)

AG

22 (46.8)

AA

16 (34.0)

G

40 (42.6)

A

54 (57.4)

COL1A1 (rs1800012)
TT

32 (69.6)

GT

14 (30.4)

GG

0 (0.0)

T

78 (84.8)

G

54 (15.2)

ACTN3 (rs1815739)
CC

21 (44.7)

CT

24 (51.1)

TT

2 (4.3)

C

66 (70.2)

T

28 (29.8)

SMAD6 (rs2053423)
CC

8 (17.0)

CT

15 (31.9)

TT

24 (51.1)

C

31 (33.0)

T

63 (67.0)

EMILIN1 (rs2289360)
GG

20 (42.6)

AG

15 (31.9)

AA

12 (25.5)

G

55 (58.5)

A

39 (41.5)

CCL2 (rs2857656)
CC

2 (4.3)

CG

24 (51.1)

GG

21 (44.7)

C

28 (29.8)

G

66 (70.2)

IGF2 (rs3213221)
CC

7 (14.9)

GC

24 (51.1)

GG

16 (34.0)

C

38 (40.4)

G

56 (59.6)

incidents were contact injuries, and 553 were non-contact injuries, with 88 injuries unclassified by the football
club personnel at the point of collection. Within injury
categories, (1) muscle injuries had 299 incidents [21
contact, 261 non-contact, 17 unclassified]; (2) tendon
injuries had 73 incidents [8 contact, 60 non-contact, 5
unclassified]; (3) ligament injuries had 304 incidents [203
contact, 73 non-contact, 28 unclassified]; and (4) bone
injuries had 111 incidents [39 contact, 66 non-contact, 6
unclassified].
Genetic associations with the total number of injuries, with muscle, tendon, ligament, and bone are presented in Table 4. The rs1372857 variant within NOGGIN
(p = 0.050) and the rs12722 variant within the COL5A1
(p = 0.028) genes were the variants associated with
all muscle-related injuries. Trends were seen for the
rs2857656 CCL2 (p = 0.082) and the rs3213221 IGF2
(p = 0.097) variants. Trends were also seen with COL1A1
rs1800012 for non-contact muscle injuries (p = 0.100)
and NOGGIN rs1372857 for contact muscle injuries
(p = 0.054). Associations were seen for the NOGGIN
rs1372857 variant for moderate (p = 0.044) and moderate and high combined (p = 0.016) severity total muscle
injuries. Trends were seen between NOGGIN rs1372857
and high severity total muscle injuries (p = 0.084), as well
as for the COL5A1 rs12722 variant for low (p = 0.073)
and moderate (p = 0.073) severity total muscle injuries.
There is an association for the rs3213221 IGF2 variant for
contact tendon injuries (p = 0.028). Trends were seen for
the rs970547 COL12A1 variant for all tendon (p = 0.084)
and non-contact tendon injuries (p = 0.079); however, an
association for the rs970547 COL12A1 variant was seen
for low severity contact tendon injuries (p = 0.026). Significant associations were found for ligament injuries,
specifically between the rs1800012 COL1A1 variant and
all ligament injuries (p = 0.019), with further associations
observed with low severity (p = 0.002), and non-contact
ligament injuries (p = 0.002), with further associations
with low severity rated non-contact injuries (p = 0.004).
The rs12722 COL5A1 variant was associated with contact bone injuries (p = 0.030), with a further association
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Table 3 Mean number of total muscle and tendon, ligament, and bone injuries when categorised by candidate variant genotype
Gene

Genotype

Muscle
Mean

Tendon
95% CI

Mean

Ligament
95% CI

Mean

Bone
95% CI

Mean

95% CI

All injuries
COL5A1

CC

4.57

[− 0.08 to 9.22]

2.14

[− 0.70 to 4.99]

6.57

[0.90 to 12.24]

1.57

[− 0.27 to 3.41]

(rs12722)

CT

6.96

[5.15 to 8.76]

1.48

[0.77 to 2.19]

8.09

[4.25 to 1.92]

2.78

[1.56 to 4.01]

TT

7.40

[3.76 to 11.13]

1.40

[0.54 to 2.26]

6.53

[2.37 to 10.69]

2.47

[1.36 to 3.57]

NOGGIN

GG

7.29

[2.67 to 11.90]

2.71

[− 0.10 to 5.53]

7.71

[1.03 to 14.40]

3.00

[1.00 to 5.00]

(rs1372857)

AG

7.73

[5.25 to 10.20]

1.27

[0.78 to 1.77]

6.73

[4.03 to 9.43]

2.82

[1.64 to 3.99]

AA

5.13

[2.59 to 7.66]

1.44

[0.37 to 2.50]

8.00

[2.39 to 13.61]

1.81

[0.61 to 3.02]

COL1A1

TT

7.00

[5.27 to 8.73]

1.59

[0.92 to 2.27]

8.72

[5.51 to 11.93]

2.69

[1.77 to 3.60]

(rs1800012)

GT

6.08

2.24 to 9.92]

1.46

[0.29 to 2.63]

3.92

[2.12 to 5.73]

2.00

[0.65 to 3.35]

GG

–

–

–

–

–

–

–

–

ACTN3

CC

8.15

[5.68 to 10.62]

1.95

[0.82 to 3.08]

8.45

[5.33 to 11.57]

2.85

[1.86 to 3.84]

(rs1815739)

CT

6.00

[3.82 to 8.18]

1.30

[0.76 to 1.85]

6.96

[3.04 to 10.87]

2.26

[1.05 to 3.47]

TT

1.00

[1.00 to 1.00]

0.50

[− 5.85 to 6.85]

0.50

[− 5.85 to 6.85]

1.50

[− 4.85 to 7.85]

SMAD6

CC

7.57

[0.63 to 14.51]

1.57

0.39 to 2.75]

4.14

[1.30 to 6.99]

3.57

[0.70 to 6.44]

(rs2053423)

CT

6.13

[3.68 to 8.59]

2.20

[0.73 to 3.67]

11.00

[5.31 to 16.69]

3.13

[1.99 to 4.28]

TT

6.87

[4.64 to 9.10]

1.13

[0.59 to 1.67]

5.91

[3.12 to 8.71]

1.74

[0.74 to 2.74]

EMILIN1

GG

6.70

[4.19 to 9.21]

1.80

[0.91 to 2.69]

8.60

[5.09 to 12.11]

2.55

[1.28 to 3.82]

(rs2289360)

AG

6.60

[4.19 to 9.01]

1.40

[0.15 to 2.65]

6.53

[1.03 to 12.04]

2.47

[1.16 to 3.77]

AA

7.00

[2.25 to 11.75]

1.30

[0.54 to 2.06]

6.00

[2.14 to 9.86]

2.40

[0.78 to 4.02]

CCL2

CC

0.00

[0.00 to 0.00]

0.00

[0.00 to 0.00]

1.00

[− 11.71 to 13.71]

3.00

[3.00 to 3.00]

(rs2857656)

CG

7.48

[5.22 to 9.73]

1.96

[0.96 to 2.95]

9.17

[4.95 to 13.40]

3.00

[1.81 to 4.19]

GG

6.55

[4.13 to 8.97]

1.25

[0.71 to 1.79]

5.85

[3.53 to 8.17]

1.85

[0.87 to 2.83]

IGF2

CC

5.00

[0.96 to 9.04]

0.83

[− 0.39 to 2.06]

5.33

[1.15 to 9.51]

1.17

[− 0.06 to 2.39]

(rs3213221)

GC

8.88

[6.54 to 11.21]

2.04

[1.07 to 3.02]

9.58

[5.54 to 13.62]

3.04

[2.18 to 3.90]

GG

4.00

[1.96 to 6.04]

1.07

[0.58 to 1.56]

4.53

[1.86 to 7.20]

2.13

[0.37 to 3.90]

COL12A1

GG

–

–

–

–

–

–

–

–

(rs970547)

AG

7.31

[3.33 to 11.28]

1.15

[0.42 to 1.89]

9.92

[2.91 to 16.93]

3.38

[2.24 to 4.53]

AA

6.23

[4.57 to 7.88]

1.74

[0.97 to 2.51]

6.19

[4.05 to 8.34]

2.10

[1.14 to 3.05]

Non-Contact Injuries
COL5A1

CC

4.14

[− 0.14 to 8.43]

1.86

[− 0.73 to 4.44]

1.00

[− 0.41 to 2.41]

1.00

[− 0.41 to 2.41]

(rs12722)

CT

6.04

[4.58 to 7.50]

1.30

[0.71 to 1.89]

1.65

[0.86 to 2.44]

1.87

[0.72 to 3.02]

TT

6.00

[2.76 to 9.24]

1.13

[0.35 to 1.91]

1.80

[0.67 to 2.93]

0.93

[0.36 to 1.51]

NOGGIN

GG

6.43

[2.62 to 10.24]

2.43

− 0.01 to 4.87]

1.86

[− 0.50 to 4.21]

1.86

[− 0.44 to 4.15]

(rs1372857)

AG

6.50

[4.28 to 8.72]

1.00

[0.61 to 1.39]

1.50

[0.83 to 2.17]

1.55

[0.46 to 2.63]

AA

4.38

[2.41 to 6.34]

1.31

[0.35 to 2.28]

1.63

[0.54 to 2.71]

1.06

[0.35 to 1.78]

COL1A1

TT

5.91

[4.43 to 7.38]

1.38

[0.78 to 1.97]

2.06

[1.35 to 2.77]

1.59

[0.84 to 2.35]

(rs1800012)

GT

5.31

[2.01 to 8.60]

1.23

[0.21 to 2.25]

0.46

[0.06 to 0.86]

1.00

[− 0.28 to 2.28]

GG

–

–

–

–

–

–

–

–

ACTN3

CC

7.20

[4.96 to 9.44]

1.55

[0.60 to 2.50]

2.10

[1.19 to 3.01]

1.90

[0.95 to 2.85]

(rs1815739)

CT

4.91

[3.24 to 6.59]

1.22

[0.66 to 1.77]

1.30

[0.56 to 2.05]

1.13

[0.19 to 2.07]

TT

0.50

[− 5.85 to 6.85]

0.50

[− 5.85 to 6.85]

0.00

[0.00 to 0.00]

0.00

[0.00 to 0.00]

SMAD6

CC

7.00

0.73 to 13.27]

1.43

[0.38 to 2.48]

0.86

[0.22 to 1.50]

2.29

[− 1.04 to 5.61]

(rs2053423)

CT

5.20

[3.13 to 7.27]

1.87

[0.58 to 3.15]

2.20

[1.03 to 3.37]

1.67

[0.84 to 2.50]

TT

5.70

[3.87 to 7.52]

0.96

[0.48 to 1.44]

1.43

[0.64 to 2.23]

1.00

[0.21 to 1.79]

EMILIN1

GG

5.60

[3.43 to 7.77]

1.35

[0.57 to 2.13]

2.00

[1.03 to 2.97]

1.50

[0.37 to 2.63]

(rs2289360)

AG

5.60

[3.75 to 7.45]

1.40

[0.30 to 2.50]

1.07

[0.17 to 1.97]

1.67

[0.49 to 2.84]

AA

6.20

[1.99 to 10.41]

1.20

[0.46 to 1.94]

1.60

[0.47 to 2.73

0.90

[− 0.02 to 1.82]

CCL2

CC

0.00

[0.00 to 0.00]

0.00

[0.00 – 0.00]

0.00

[0.00 to 0.00]

0.50

[− 5.85 to 6.85]
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Table 3 (continued)
Gene

Genotype

Muscle
Mean

(rs2857656)

Tendon
95% CI

Mean

Ligament
95% CI

Mean

Bone
95% CI

Mean

95% CI

CG

6.48

[4.54 to 8.41]

1.74

[0.86 to 2.62]

1.87

[0.88 to 2.86]

2.04

[0.96 to 3.13]

GG

5.45

[3.42 to 7.48]

1.00

[0.54 to 1.46]

1.45

[0.89 to 2.01]

0.80

[0.16 to 1.44]

IGF2

CC

4.17

[1.02 to 7.31]

0.50

[− 0.38 to 1.38]

1.50

[0.40 to 2.60]

0.67

[− 0.60 to 1.94]

(rs3213221)

GC

7.50

[5.46 to 9.54]

1.67

[0.80 to 2.54]

2.08

[1.16 to 3.01]

1.54

[0.81 to 2.28]

GG

3.53

[1.81 to 5.26]

1.13

[0.67 to 1.60]

0.87

[0.21 to 1.52]

1.53

[− 0.03 to 3.10]

COL12A1

GG

–

–

–

–

–

–

–

–

(rs970547)

AG

6.31

[2.78 to 9.83]

0.92

[0.46 to 1.38]

1.85

[0.41 to 3.28]

2.15

[0.92 to 3.38]

AA

5.23

[3.90 to 6.55]

1.52

[0.82 to 2.21]

1.52

[0.92 to 2.11]

1.13

[0.36 to 1.90]

Contact injuries
COL5A1

CC

0.29

[− 0.17 to 0.74]

0.29

[− 0.17 to 0.74]

5.14

[1.28 to 9.01]

0.57

[− 0.33 to 1.47]

(rs12722)

CT

0.61

[0.20 to 1.02]

0.13

[− 0.02 to 0.28]

4.61

[3.00 to 6.22]

0.65

[0.23 to 1.08]

TT

0.33

[− 0.01 to 0.68]

0.20

[− 0.03 to 0.43]

4.07

[1.29 to 6.85]

1.27

[0.47 to 2.06]

NOGGIN

GG

0.43

[− 0.07 to 0.92]

0.29

[− 0.17 to 0.74]

5.29

[1.48 to 9.09]

1.14

[0.02 to 2.27]

(rs1372857)

AG

0.55

[0.25 to 0.84]

0.23

[0.04 to 0.42]

4.32

[2.49 to 6.15]

0.91

[0.46 to 1.36]

AA

0.38

[− 0.17 to 0.92]

0.06

[− 0.07 to 0.20]

4.44

[2.04 to 6.84]

0.65

[− 0.10 to 1.35]

COL1A1

TT

0.59

[0.28 to 0.91]

0.22

[0.07 to 0.37]

5.09

[3.42 to 6.77]

0.94

[0.49 to 1.39]

(rs1800012)

GT

0.15

[− 0.07 to 0.38]

0.08

[− 0.09 to 0.24]

3.08

[1.67 to 4.48]

0.62

[0.03 to 1.20]

GG

–

–

–

–

–

–

–

–

ACTN3

CC

0.45

[0.13 to 0.77]

0.25

[0.04 to 0.46]

5.45

[3.43 to 7.47]

0.80

[0.35 to 1.25]

(rs1815739)

CT

0.52

[0.13 to 0.91]

0.13

[− 0.02 to 0.28]

4.09

[2.35 to 5.82]

0.87

[0.27 to 1.47]

TT

0.00

[0.00 to 0.00]

0.00

[0.00 to 0.00]

0.00

[0.00 to 0.00]

1.00

[1.00 to 1.00]

SMAD6

CC

0.29

[− 0.17 to 0.74]

0.00

[0.00 to 0.00]

2.86

[0.69 to 5.02]

0.86

[− 0.27 to 1.98]

(rs2053423)

CT

0.53

[0.18 to 0.89]

0.27

[0.01 to 0.52]

6.20

[3.77 to 8.63]

1.13

[0.51 to 1.76]

TT

0.48

[0.07 to 0.89]

0.17

[0.01 to 0.34]

3.91

[2.08 to 5.75]

0.65

[0.14 to 1.17]

EMILIN1

GG

0.50

[0.18 to 0.82]

030

[0.08 to 0.52]

5.40

[3.15 to 7.65]

0.85

[0.26 to 1.44]

(rs2289360)

AG

0.33

[0.06 to 0.60]

0.07

[− 0.08 to 0.21]

3.80

[1.88 to 5.72]

0.60

[0.14 to 1.06]

AA

0.60

[− 0.30 to 1.50]

0.10

[− 0.13 to 0.33]

3.80

[1.04 to 6.56]

1.20

[0.20 to 2.20]

CCL2

CC

0.00

[0.00 to 0.00]

0.00

[0.00 – 0.00]

0.50

[− 5.85 to 6.85]

1.00

[− 11.71 to 13.71]

(rs2857656)

CG

0.48

[0.09 to 0.87]

0.17

[0.01 to 0.34]

5.52

[3.51 to 7.53]

0.78

[0.26 to 1.30]

GG

0.50

[0.18 to 0.82]

0.20

[0.01 to 0.39]

3.75

[2.14 to 5.36]

0.90

[0.35 to 1.45]

IGF2

CC

0.50

[− 0.38 to 1.38]

0.33

[− 0.21 to 0.88]

3.50

[0.55 to 6.45]

0.50

[− 0.38 to 1.38]

(rs3213221)

GC

0.63

[0.23 to 1.02]

0.25

[0.06 to 0.44]

5.67

[3.71 to 7.62]

1.29

[0.76 to 1.83]

GG

0.20

[− 0.03 to 0.43]

0.00

[0.00 to 0.00]

3.07

[1.15 to 4.98]

0.27

[− 0.18 to 0.71]

COL12A1

GG

–

–

–

–

–

–

–

–

(rs970547)

AG

0.46

[0.06 to 0.86]

0.08

[− 0.09 to 0.24]

5.54

[2.53 to 8.55]

0.85

[0.25 to 1.44]

AA

0.45

[0.14 to 0.76]

0.23

[0.07 to 0.38]

4.00

[2.59 to 5.41]

0.81

[0.35 to 1.26]

seen with the number of moderate severity injuries
(p = 0.049). A trend was also seen with respect to the
number of moderate and high combined severity injuries
(p = 0.065).
The NOGGIN rs1372857 variant had an IRR of 0.813
[0.66 to 1.00] for total muscle injuries, with analysis finding those with the NOGGIN GG genotype experiencing an estimated number of injuries per game of 8.44
[6.16 to 1.71], compared to 6.86 [7.27 to 9.40] for the

heterozygous genotype and 5.58 [4.28 to 6.87] for the
AA genotype. When examining moderate severity injuries, the IRR was 0.691 [0.48 to 0.99], with the estimated
number of injuries being 3.45 (GG) [1.88 to 5.01], 2.38
(AG) [1.80 to 2.95], and 1.64 (AA) [0.96 to 2.32]. When
analysing moderate and high severity injuries, the IRR
was 0.639 [0.44 to 0.92], with the estimated number of
injuries being 4.71 (GG) [2.53 to 6.89], 3.01 (AG) [2.27 to
3.74], and 1.92 (AA) [1.13 to 2.72].

0.813

0.044

0.967

0.055

0.845

0.034

1.103

0.040

1.040

0.023

1.292

0.066

0.814

0.051

Intercept

NOGGIN

Intercept

COL1A1

Intercept

ACTN3

Intercept

SMAD6

Intercept

EMILIN1

Intercept

CCL2

Intercept

IGF2

Intercept

COL12A1

NOGGIN

(rs1372857)

COL1A1

(rs1800012)

ACTN3

(rs1815739)

SMAD6

(rs2053423)

EMILIN1

(rs2289360)

CCL2

(rs2857656)

IGF2

(rs3213221)

COL12A1

(rs970547)

0.057

0.810

0.036

1.009

0.051

0.795

0.032

1.057

0.032

1.069

0.022

Intercept

NOGGIN

Intercept

COL1A1

Intercept

ACTN3

Intercept

SMAD6

Intercept

EMILIN1

Intercept

CCL2

NOGGIN

(rs1372857)

COL1A1

(rs1800012)

ACTN3

(rs1815739)

SMAD6

(rs2053423)

EMILIN1

(rs2289360)

CCL2

(rs2857656)

0.170

0.000

0.483

0.000

0.588

0.000

0.110

0.000

0.961

0.000

0.054

0.000

0.120

0.000

0.623

0.000

0.097

0.000

0.082

0.000

0.672

0.000

0.317

0.000

0.226

0.000

0.842

[0.91 to 1.67]

[0.01 to 0.05]

[0.89 to 1.29]

[0.02 to 0.05]

[0.87 to 1.29]

[0.02 to 0.05]

[0.60 to 1.05]

[0.03 to 0.08]

[0.72 to 1.42]

[0.02 to 0.06]

[0.66 to 1.00]

[0.04 to 0.09]

[0.96 to 1.48]

[0.02 to 0.04]

[0.72 to 1.22]

[0.03 to 0.10]

[0.64 to 1.04]

[0.04 to 0.11]

[1.00 to 1.23]

[0.01 to 0.05]

[0.88 to 1.25]

[0.03 to 0.06]

[0.91 to 1.34]

[0.02 to 0.05]

[0.64 to 1.11]

[0.04 to 0.09]

[0.69 to 1.34]

[0.03 to 0.07]

[0.66 to 1.00]

0.050
0.000

[0.04 to 0.11]

[1.03 to 1.53]

0.000

[0.02 to 0.04]

0.000
0.028

0.812

0.014

0.950

0.009

0.907

0.010

0.991

0.009

1.042

0.008

0.811

0.013

0.882

0.011

1.698

0.002

0.996

0.010

0.887

0.013

0.824

0.014

0.938

0.011

0.861

0.012

1.087

0.009

0.802

0.016

0.920

0.012

0.480

< 0.001

0.798

0.000

0.644

0.000

0.974

0.000

0.906

0.000

0.324

0.000

0.582

0.000

0.084

< 0.001

0.988

< 0.001

0.679

< 0.001

0.320

0.000

0.758

0.000

0.594

0.000

0.808

0.000

0.285

0.000

0.705

0.000

p value

[0.46 to 1.45]

[0.00 to 0.05]

[0.64 to 1.40]

[0.00 to 0.02]

[0.60 to 1.37]

[0.00 to 0.03]

[0.57 to 1.73]

[0.00 to 0.02]

[0.52 to 2.08]

[0.00 to 0.02]

[0.54 to 1.23]

[0.00 to 0.03]

[0.57 to 1.38]

[0.00 to 0.03]

[0.93 to 3.10]

[0.00 to 0.01]

[0.59 to 1.69]

[0.00 to 0.03]

[0.50 to 1.56]

[0.00 to 0.05]

[0.56 to 1.21]

[0.01 to 0.03]

[0.62 to 1.41]

[0.00 to 0.03]

[0.50 to 1.49]

[0.01 to 0.03]

[0.55 to 2.13]

[0.00 to 0.02]

[0.54 to 1.20]

[0.01 to 0.04]

[0.60 to 1.42]

[0.00 to 0.03]

95% CI

1.128

0.007

0.834

0.014

1.191

0.007

0.745

0.015

0.255

0.049

1.081

0.008

1.384

0.005

0.812

0.080

0.799

0.076

0.756

0.091

0.826

0.063

1.074

0.040

1.031

0.045

0.567

0.090

1.038

0.043

1.114

0.037

IRR

Ligament

0.669

< 0.001

0.313

0.000

0.388

0.000

0.275

[0.65 to 1.96]

[0.00 to 0.03]

[0.59 to 1.19]

[0.01 to 0.03]

[0.80 to 1.77]

[0.00 to 0.02]

[0.44 to 1.26]

[0.01 to 0.04]

[0.11 to 0.60]

0.002
0.000

[0.02 to 0.13]

[0.71 to 1.64]

[0.00 to 0.02]

[0.91 to 2.10]

[0.00 to 0.01]

[0.60 to 1.10]

[0.04 to 0.17]

[0.53 to 1.20]

[0.03 to 0.18]

[0.49 to 1.17]

[0.03 to 0.25]

[0.64 to 1.07]

[0.04 to 0.10]

[0.83 to 1.40]

[0.02 to 0.08]

[0.69 to 1.54]

< 0.001

0.712

0.000

0.127

0.000

0.181

< 0.001

0.277

< 0.001

0.208

< 0.001

0.141

0.000

0.590

0.000

0.884

[0.02 to 0.08]

[0.35 to 0.91]

0.019
0.000

[0.05 to 0.17]

[0.74 to 1.46]

[0.02 to 0.10]

[0.81 to 1.53]

[0.02 to 0.08]

95% CI

< 0.001

0.833

< 0.001

0.504

0.000

p value

0.586

0.031

0.897

0.011

0.704

0.020

0.746

0.014

0.711

0.014

0.837

0.013

0.919

0.11

0.920

0.019

1.393

0.007

0.646

0.042

0.905

0.018

0.844

0.022

0.972

0.016

0.763

0.021

0.820

0.024

1.206

0.10

IRR

Bone

0.160

< 0.001

0.693

0.000

0.204

< 0.001

0.448

< 0.001

0.476

< 0.001

0.549

< 0.001

0.802

< 0.001

0.639

0.000

0.093

0.000

0.093

< 0.001

0.506

0.000

0.207

0.000

0.896

0.000

0.360

0.000

0.159

< 0.001

0.244

0.000

p value

[0.28 to 1.24]

[0.01 to 0.19]

[0.53 to 1.54]

[0.00 to 0.03]

[0.41 to 1.21]

[0.01 to 0.07]

[0.35 to 1.59]

[0.00 to 0.05]

[0.28 to 1.82]

[0.00 to 0.05]

[0.47 to 1.50]

[0.00 to 0.05]

[0.48 to 1.78]

[0.00 to 0.05]

[0.65 to 1.30]

[0.00 to 0.05]

[0.95 to 2.05]

[0.00 to 0.02]

[0.39 to 1.08]

[0.01 to 0.13]

[0.67 to 1.21]

[0.01 to 0.03]

[0.65 to 1.10]

[0.01 to 0.04]

[0.63 to 1.50]

[0.01 to 0.03]

[0.43 to 1.36]

[0.01 to 0.04]

[0.60 to 1.09]

[0.01 to 0.04]

[0.88 to 1.65]

[0.00 to 0.02]

95% CI

(2022) 8:126

1.236

1.188

COL5A1

(rs12722)

0.025

Intercept

COL5A1

Non-contact injuries

0.066

COL5A1

0.937

1.253

Intercept

(rs12722)

0.026

IRR

95% CI

IRR

p value

Tendon

Muscle

COL5A1

All injuries

Variant

Table 4 Negative binominal model of genetic variants and total number of muscle, tendon, ligament, and bone-related injuries
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COL12A1

(rs970547)

0.930

0.012

0.294

0.002

1.273

0.001

1.341

0.003

1.040

0.001

1.349

0.010

0.559

0.003

NOGGIN

Intercept

COL1A1

Intercept

ACTN3

Intercept

SMAD6

Intercept

EMILIN1

Intercept

CCL2

Intercept

IGF2

Intercept

COL12A1

(rs1372857)

COL1A1

(rs1800012)

ACTN3

(rs1815739)

SMAD6

(rs2053423)

EMILIN1

(rs2289360)

CCL2

(rs2857656)

IGF2

(rs3213221)

COL12A1

(rs970547)

Significant effects are bolded

0.003

Intercept

NOGGIN

0.987

1.021

COL5A1

(rs12722)

0.003

Intercept

COL5A1

Contact injuries

0.049

Intercept

COL12A1

0.894

0.838

IGF2

0.053

Intercept

(rs3213221)

0.974

< 0.001

0.146

< 0.001

0.477

< 0.001

0.889

0.000

0.353

< 0.001

0.545

0.000

0.100

< 0.001

0.824

< 0.001

0.950

< 0.001

0.405

0.000

0.175

0.000

[0.46 to 2.14]

[0.00 to 0.02]

[0.26 to 1.23]

[0.00 to 0.05]

[0.59 to 3.08]

[0.00 to 0.01]

[0.60 to 1.81]

[0.00 to 0.01]

[0.72 to 2.49]

[0.00 to 0.01]

[0.58 to 2.79]

[0.00 to 0.01]

[0.07 to 1.26]

[0.00 to 0.06]

[0.49 to 1.76]

[0.00 to 0.01]

[0.53 to 1.97]

[0.00 to 0.01]

[0.69 to 1.16]

[0.02 to 0.10]

[0.65 to 1.08]

[0.03 to 0.09]

3.506

< 0.001

0.249

0.017

1.469

< 0.001

0.447

0.004

1.567

< 0.001

0.638

0.002

0.399

0.003

0.528

0.004

0.979

0.001

1.750

0.002

1.272

0.005

IRR

95% CI

IRR

p value

Tendon

Muscle

IGF2

Variant

Table 4 (continued)

0.225

[0.46 to 26.62]

[0.00 to 0.01]

[0.07 to 0.86]

0.028
< 0.001

[0.00 to 0.17]

[0.39 to 5.58]

[0.00 to 0.01]

[0.14 to 1.39]

[0.00 to 0.02]

[0.55 to 4.46]

[0.00 to 0.01]

[0.16 to 2.52]

[0.00 to 0.02]

[0.05 to 3.24]

[0.00 to 0.04]

[0.19 to 1.45]

[0.01 to 0.03]

[0.35 to 2.76]

[0.00 to 0.01]

[0.94 to 2.37]

[0.00 to 0.01]

[0.74 to 2.20]

[0.00 to 0.02]

95% CI

< 0.001

0.572

< 0.001

0.163

< 0.001

0.400

< 0.001

0.521

< 0.001

0.390

< 0.001

0.216

< 0.001

0.967

< 0.001

0.079

< 0.001

0.389

< 0.001

p value

0.896

0.038

0.865

0.039

0.963

0.031

0.830

0.039

1.130

0.021

0.840

0.037

0.727

0.042

0.998

0.028

0.906

0.035

1.085

0.008

0.648

0.025

IRR

Ligament

0.562

< 0.001

0.392

0.000

0.845

< 0.001

0.143

0.000

0.399

0.000

0.364

0.000

0.184

0.000

0.989

0.000

0.518

0.000

0.765

< 0.001

0.082

< 0.001

p value

[0.62 to 1.30]

[0.01 to 0.10]

[0.62 to 1.21]

[0.02 to 0.08]

[0.66 to 1.41]

[0.01 to 0.08]

[0.65 to 1.07]

[0.02 to 0.06]

[0.85 to 1.50]

[0.01 to 0.04]

[0.58 to 1.22]

[0.02 to 0.07]

[0.46 to 1.16]

[0.02 to 0.08]

[0.75 to 1.33]

[0.02 to 0.05]

[0.67 to 1.22]

[0.02 to 0.07]

[0.64 to 1.86]

[0.00 to 0.03]

[0.40 to 1.06]

[0.01 to 0.07]

95% CI

0.946

0.006

0.603

0.015

1.066

0.005

1.175

0.004

–

–

1.552

0.003

0.736

0.008

0.768

0.009

1.824

0.001

0.561

0.041

1.071

0.008

IRR

Bone

0.856

< 0.001

0.108

< 0.001

0.858

< 0.001

0.491

0.000

–

–

0.151

0.000

0.502

< 0.001

0.288

[0.52 to 1.72]

[0.00 to 0.03]

[0.33 to 1.12]

[0.00 to 0.06]

[0.53 to 2.13]

[0.00 to 0.03]

[0.74 to 1.86]

[0.00 to 0.01]

–

–

[0.85 to 2.83]

[0.00 to 0.01]

[0.30 to 1.80]

[0.00 to 0.03]

[0.47 to 1.25]

[0.00 to 0.03]

[1.06 to 3.13]
0.000

[0.00 to 0.01]
0.030

[0.25 to 1.28]

[0.00 to 0.37]

[0.54 to 2.14]

[0.00 to 0.04]

95% CI

0.000

0.170

0.005

0.846

< 0.001

p value
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The COL5A1 rs12722 variant had an IRR of 1.253 [1.03
to 1.53] for total muscle injuries, with the TT genotype
having a higher estimated number of injuries per game
(8.00 [6.37 to 9.61]) than the CT (6.38 [5.50 to 7.25]) and
CC genotypes (5.09 [3.67 to 6.51]).
In terms of contact tendon injuries, the IGF2 rs3213221
variant had an IRR of 0.249 [0.07 to 0.86], with the CC
genotype (0.66 [− 0.11 to 1.44] having a higher estimated
number of injuries per games than the CG (0.17 [0.04 to
0.29]) and GG (0.04 [− 0.03 to 0.11]) genotypes. When
investigating low severity contact tendon injuries, the
IRR was 0.222 [0.06 to 0.84], with the CC genotype (0.63
[− 0.13 to 1.40] having a higher estimated number of injuries per games than the CG (0.14 [0.02 to 0.26]) and GG
(0.03 [− 0.03 to 0.09]) genotypes.
For the COL1A1 rs1800012 variant, with an observed
IRR of 0.567 [0.35 to 0.91] for total ligament injuries, carriers of the TT genotype experienced an estimated number of injures per game of 8.12 [6.31 to 9.92], compared
to 4.61 [2.69 to 6.52] for the heterozygous genotype. The
GG genotype was not represented in the current population. The IRR for low severity injuries was 0.602 [0.38
to 0.94], with the estimated number of injuries of the TT
and GT genotypes being 7.00 [5.61 to 8.40] and 4.21 [2.52
to 5.91], respectively. For non-contact ligament injuries,
the rs1800012 variant had an IRR of 0.255 [0.11 to 0.60],
with the TT genotype having a higher estimated number of injuries per game (1.99 [1.48 to 2.50]) compared
to the GT genotype (0.51 [0.10 to 0.92]). When analysing
low severity non-contact ligament injuries, the IRR was
0.243, with the TT genotype (1.75 [1.22 to 2.27]) having
a higher number of estimated injuries per game than the
GT genotype (0.42 [0.04 to 0.81]).
For contact bone injuries, the COL5A1 rs12722 variant
had an IRR of 1.824 [1.06 to 3.13] with the TT genotype
(1.28 [0.66 to 1.90]) having a higher number of estimated
injuries per game compared to the CT (0.70 [0.42 to
0.98]) and CC genotypes (0.38 [0.07 to 0.70]). There were
significant associations for moderate contact bone injuries with an IRR of 2.82 [1.01 to 1.89] with TT genotype
(0.47 [0.12 to 0.82]) having a higher number of estimated
injuries per game compared to the CT (0.17 [0.03 to
0.30]) and CC genotypes (0.06 [− 0.04 to 0.16]).

Discussion
Our preliminary investigation into the association of candidate genetic variants with injury number and severity
in elite AFL players resulted in novel findings, and the
identification of novel genetic markers for injury classification within AF. We discovered an association between
the NOGGIN polymorphism (rs1372857) and all muscle injuries, with significantly higher muscle injury incidence for those with the GG genotype, which also trended
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towards moderate-to-high combined severity injuries.
The rs1372857 variant within the NOGGIN gene has been
linked to bone fractures in a clinical study investigating motor vehicle accident, fall, and direct blow patients
[31], with the homozygous GG genotype associated with
non-union fractures [31]. While we did not identify a
relationship between rs1372857 and bone injuries in our
AFL cohort, we did observe a similar link between the GG
genotype and a larger number of total injuries per season,
together with more moderate-to-high severity of injuries.
Given the inextricable link between muscle, tendon, and
bone, and their co-adaptive processes [9], it seems reasonable to observe some crossover with NOGGIN expression
and injuries to these tissues. Further research needs to be
done to confirm whether this association between genetic
variants within NOGGIN and subsequent muscle and tendon injuries in AFL players exists.
The current study found an association between the
COL5A1 rs12722 polymorphism and all muscle injuries, with the TT genotype having a higher estimated
number of injuries per game. This follows previously
reported associations between the CC genotype of
rs12722 and less severe non-contact muscle injuries in
soccer players [26, 55]. However, the variant was also
found to show no significant difference between muscle
injury and no muscle injury groups in a Japanese group
of varied athletes [44]. The COL5A1 gene encodes for
the collagen type V α1 chain of protein and forms part
of the extracellular matrix of skeletal muscles and can
affect passive muscle stiffness as well as joint flexibility
[56, 57]. The rs12722 polymorphism has also been associated with a higher susceptibility to ligament injuries
[58]. We also found significant associations between the
rs12722 TT genotype, contact bone injuries, and moderate severity contact bone injuries. Due to the findings
being with contact, the polymorphism may have more
of an effect on response to acute trauma.
We also found an association with the IGF2 rs3213221
polymorphism and contact tendon injuries. This variant has previously been linked with tendon and muscle
injuries in elite Caucasian soccer players, with a higher
number of tendon injuries related to the presence of the
C allele [59]. Our study found that those with the CC
genotype had a higher estimated number of injuries per
game compared to its counterparts, which coincides with
previous findings. IGF2 plays a role in modulating satellite cell activation and differentiation, thereby affecting
soft tissue growth, as well as response to cell degeneration and regeneration following injury [26, 60].
Our study also discovered a significant association
between the total number of ligament injuries with the
rs1800012 variant of the COL1A1 gene, with a significantly higher likelihood of low severity ligament-related
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injuries in those with the COL1A1 TT genotype, and a
significant association between non-contact ligament
injuries. These results are contradictory to previous
research that has found that those with the TT genotype
had less prevalence of ACL injuries [61] and cruciate ligament or shoulder dislocation injuries [62]. The COL1A1
gene encodes the protein chain in type 1 collagen, a
structural component in ligaments [61]. The T allele of
the COL1A1 gene is associated with an increased production the protein chain in type 1 collagen [62]. Previous
studies have investigated the effect of collagen peptides in
muscle damage post-eccentric training [63] and in posttraumatic osteoarthritis in mice [64] and suggest that the
supplementation of collagen may reduce inflammation.
It has also been suggested that the increased production
of the protein chain in type 1 collagen associated with
the T allele increases the tensile strength of tendons and
ligaments; however, the precise mechanism is unknown
[62]. The contradictory results of the current study could
be due to the GG genotype not being represented in the
current population. Similarly, ligament injuries are multifactorial, ligaments are passive anatomical structures,
and injuries cannot be solely predicted by genetic variations alone; thus, it could be the significant association
between the COL1A1 TT genotype and low-grade ligament injuries which infers a possible protective effect
resulting in lower-grade rather than higher-grade injuries
when the injurious events occur. This is speculative and
would require thorough exploration of these associations
and implications between COL1A1 and the TT genotype
with ligament injuries in AFL more broadly.
Stress fractures are prevalent in AF, particularly for
first- and second-year players who have less training and
game experience at the elite level, and immature or developing physical structures yet to wholly tolerate these
elevated physical demands [7, 11, 49, 65]. Although our
study found no significant result between bone injuries
and the genetic variants we explored in our AFL cohort,
this may be due to the prospective observation of the
same forty-six of various physical maturity overtime.
Instead, for bone stress injuries (as disparate from other
injury types), it may be better for future studies to prospectively observe early career AFL players in their first
two seasons [66], who are typical candidates for stress
fractures [65, 67], and use these early career cohorts to
delineate genetic variant differences between those who
sustain or avoid stress fractures. Despite previous associations with bone mineral density, the variant within the
SMAD6 gene had no significant association within the
current study.
This study has several strengths and limitations that
warrant acknowledgement. This is the first study to
explore the associations between a select panel of genetic
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variants to different types of injuries in elite AFL players.
Another strength was the collection of injury incidence
and severity data over 7 consecutive years using the
AFL’s highly standardised and reliable injury recording
and reporting methods. However, our study’s limitations
include its small sample size for a genetic study, and the
single elite AFL squad investigated, ensuring the results
must be delimited to this one cohort. Age represents one
important contributor to injury risk though it was unable
to be evaluated in our statistical model. In addition, the
panel of genes included in this study will not be reflective of all genetic variants that may be important, and
thus, our results are also delimited to the gene candidates
evaluated. Replication of the current study using as many
elite AFL teams as possible (i.e. preferably competitionwide studies), and broader range of genetic variants of
interest, would be recommended to maximise this line of
investigation and seek to confirm our findings into elitelevel male footballers and the genetic underpinnings of
injury incidence and severity. Lastly, predisposition to, or
associations with, injuries is likely to be highly complex
and polygenic in nature; thus, future research could focus
on the cumulative impact of genetic variation assessed
through polygenic risk scores, such as the total genotype
score (TGS) method [68]. Regardless, our preliminary
study raises some intriguing insights into potential relationships among genotypes and its link to injury incidence and severity that warrants further investigation.

Conclusion
Several novel and significant associations were found
during the current study. The rs12722 SNP within the
COL5A1 gene was significantly associated with all muscle injuries, as was NOGGIN rs1372857, while COL5A1
was also significantly associated with contact bone injuries. The IGF2 rs3213221 polymorphism was significantly associated with contact tendon injuries, while the
COL1A1 rs1800012 gene was significantly associated
with all ligament injuries, with further associations with
low severity injuries and non-contact ligament injuries. Several trends towards significance were observed
between CCL2 rs2857656 and IGF2 rs3213221 for all
muscle injuries, between COL1A1 rs1800012 and contact
muscle injuries, between NOGGIN rs1372857 and noncontact muscle injuries, and COL12A1 rs970547 and all
tendon and non-contact tendon injuries. Future research
should expand the population pool by undertaking a
competition-wide study and may investigate how such
genetic variants could influence a person’s injury rate
when compared to playing position, physiological abilities, and training loads or exposure time (hours of training and competition) across a season. Future research
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should replicate this work in elite female Australian Football (AFLW) population.
These findings present potential applications for developing training regimes around genetic predisposition.
Players who are known to have a higher risk of injury due
to underlying genetic susceptibilities could have more
specific training based around their individual needs,
including targeted and specific strength programs, and
more scrutinised loading practises to reduce injury onset.
For example, elite male Australian Football players with
genotypes associated with potential susceptibility to
bone-related injuries should be prioritised for (1) closer
screening and ongoing monitoring of lower-body musculoskeletal morphology status and training adaptation
through dual-energy X-ray absorptiometry (DXA) and
peripheral quantitative computed tomography (pQCT)
if available; (2) individualised load management practices
with lower running volumes (relative to others) in favour
of targeted lower-body mechanical loading programs
honouring osteogenic principles of mechano-adaptation (i.e. high-magnitude, low-volume strength training,
or multi-directional plyometric exercises) to optimise
musculoskeletal cross-sectional area, promote skeletal robustness, and improve skeletal fatigue resistance
[69–72]; and (3) nutritional review by a sports dietitian
to evaluate energy availability, calcium, and vitamin D
intake for potential supplementation in accordance with
the Australian Football Anti-Doping Code (signatory
to the World Anti-Doping Code, World Anti-Doping
Agency (WADA)) [73–75].
Abbreviations
ACL: Anterior Cruciate Ligament; ACTN3: Alpha-Actinin-3; AF: Australian
Football; AFL: Australian Football League; AFLW: Australian Football League
Women; AGRF: Australian Genome Research Facility; BMP: Bone Morphogenetic Proteins; CCL2: Chemokine CC Motif Ligand-2; COL1A1: Collagen Type I
Alpha 1; COL12A1: Collagen Type XII Alpha 1; COL5A1: Collagen Type V Alpha
1; DNA: Deoxyribonucleic Acid; DXA: Dual-energy X-ray Absorptiometry;
EMILIN1: Elastin Microfibril Interface 1; HWE: Hardy–Weinberg Equilibrium;
IGF2: Insulin-like Growth Factor-2; IRRs: Incident Rate Ratios; pQCT: Peripheral
Quantitative Computed Tomography; SMAD6: SMAD Family Member 6; SNP:
Single Nucleotide Polymorphism; TGS: Total Genotype Score; WADA: World
Anti-Doping Agency; WAFL: Western Australian Football League.
Acknowledgements
Results of this study have been presented clearly, honestly, and without fabrication, falsification, or inappropriate data manipulation. The authors declare
no conflicts of interest. The authors would also like to acknowledge the
West Coast Eagle Football Club and their players for their participation in this
research. The authors would like to also thank the Australian Football League
for their approval and support for this research to occur.
Author Contributions
YJ, RSA, TS, and NHH conceptualised the research. YJ, TS, NHH, BR, and AJ collected the data. YJ, RSA, JLCW, DH, SML, and NHH conducted data analysis. DH
provided biostatistical support to YJ and the study. All authors were involved
in manuscript drafting, data interpretation, manuscript completion, and revisions during the review process.

Page 12 of 14

Funding
No funding was received to complete this research. YJ is supported by an
Australian Government Research Training Scholarship.
Availability of Data and Materials
Raw datasets generated and analysed during this study are not publicly available due to agreement with the football club, and to protect the confidentiality and individual privacy of the athlete participants within the elite football
club.

Declarations
Ethics Approval and Consent to Participate
Data collection and management procedures conformed to the Declaration
of Helsinki (World Medical Association). Human Research Ethics Approval was
provided by the Edith Cowan University Human Research and Ethics Committee (ID: 2019-00181-JACOB). All participants provided written informed
consent to participate in this study.
Consent for Publication
Not applicable.
Competing interests
BR is an employee of the West Coast Eagles Football Club, and AJ was an
employee of the West Coast Eagles Football Club at the time of data collection and analysis. No other financial or non-financial competing interests are
declared by any authors.
Author details
1
School of Medical and Health Sciences, Edith Cowan University, Perth, WA,
Australia. 2 Institute for Health Research, University of Notre Dame Australia,
Perth, WA, Australia. 3 School of Health Science, University of Notre Dame
Australia, Perth, WA, Australia. 4 Exercise Medicine Research Institute, Edith
Cowan University, WA, Perth, Australia. 5 West Coast Eagles Football Club, Perth,
WA, Australia. 6 Centre for Precision Health, Edith Cowan University, Perth, WA,
Australia. 7 Collaborative Genomics and Translation Group, School of Medical
and Health Sciences, Edith Cowan University, Perth, WA, Australia. 8 School
of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin
Health Innovation Research Institute, Curtin University, Perth, WA, Australia.
9
Caring Futures Institute, College of Nursing and Health Sciences, Flinders
University, Adelaide, SA, Australia. 10 Faculty of Health, School of Nursing,
Queensland University of Technology, Brisbane, QLD, Australia.
Received: 21 March 2022 Accepted: 29 September 2022

References
1. Boyd LJ, Ball K, Aughey RJ. Quantifying external load in Australian football
matches and training using accelerometers. Int J Sports Physiol Perform.
2013;8(1):44–51.
2. Coutts AJ, Quinn J, Hocking J, Castagna C, Rampinini E. Match running performance in elite Australian Rules Football. J Sci Med Sport.
2010;13(5):543–8.
3. Gray AJ, Jenkins DG. Match analysis and the physiological demands of
Australian football. Sports Med. 2010;40(4):347–60.
4. Wisbey B, Montgomery PG, Pyne DB, Rattray B. Quantifying movement demands of AFL football using GPS tracking. J Sci Med Sport.
2010;13(5):531–6.
5. Colby MJ, Dawson B, Heasman J, Rogalski B, Rosenberg M, Lester L, et al.
Preseason workload volume and high-risk periods for noncontact injury
across multiple Australian football league seasons. J Strength Cond Res.
2017;31(7):1821–9.
6. Hart NH, Nimphius S, Cochrane JL, Newton RU. Leg mass characteristics
of accurate and inaccurate kickers: an Australian football perspective. J
Sports Sci. 2013;31(15):1647–55.

Jacob et al. Sports Medicine - Open

7.
8.
9.
10.

11.
12.
13.
14.
15.

16.
17.
18.
19.
20.
21.
22.
23.

24.
25.
26.

27.

28.

(2022) 8:126

Hart NH, Nimphius S, Spiteri T, Cochrane JL, Newton RU. Relationship
between Leg Mass, Leg Composition and Foot Velocity on Kicking Accuracy in Australian Football. J Sports Sci Med. 2016;15(2):344–51.
Hart NH, Nimphius S, Spiteri T, Newton RU. Leg strength and lean mass
symmetry influences kicking performance in Australian football. J Sports
Sci Med. 2014;13(1):157–65.
Hart NH, Nimphius S, Weber J, Spiteri T, Rantalainen T, Dobbin M, et al.
Musculoskeletal asymmetry in football athletes: a product of limb function over time. Med Sci Sports Exerc. 2016;48(7):1379–87.
Hart NH, Spiteri T, Lockie RG, Nimphius S, Newton RU. Detecting deficits
in change of direction performance using the preplanned multidirectional Australian football league agility test. J Strength Cond Res.
2014;28(12):3552–6.
Saw R, Finch CF, Samra D, Baquie P, Cardoso T, Hope D, et al. Injuries in
Australian rules football: an overview of injury rates, patterns, and mechanisms across all levels of play. Sports Health. 2018;10(3):208–16.
Eirale C, Tol JL, Farooq A, Smiley F, Chalabi H. Low injury rate strongly correlates with team success in Qatari professional football. Br J Sports Med.
2013;47(12):807–8.
Collins M, Raleigh SM. Genetic risk factors for musculoskeletal soft tissue
injuries. Med Sport Sci. 2009;54:136–49.
McCabe K, Collins C. Can genetics predict sports injury? The Association
of the genes GDF5, AMPD1, COL5A1 and IGF2 on soccer player injury
occurrence. Sports. 2018;6(1):21.
McCall A, Carling C, Davison M, Nedelec M, Le Gall F, Berthoin S, et al.
Injury risk factors, screening tests and preventative strategies: a systematic review of the evidence that underpins the perceptions and practices
of 44 football (soccer) teams from various premier leagues. Br J Sports
Med. 2015;49(9):583–9.
Baumert P, Lake MJ, Stewart CE, Drust B, Erskine RM. Genetic variation and
exercise-induced muscle damage: implications for athletic performance,
injury and ageing. Eur J Appl Physiol. 2016;116(9):1595–625.
Kim JH, Jung ES, Kim CH, Youn H, Kim HR. Genetic associations of body
composition, flexibility and injury risk with ACE, ACTN3 and COL5A1 polymorphisms in Korean ballerinas. J Exerc Nutr Biochem. 2014;18(2):205–14.
Maciejewska-Skrendo A, Leznicka K, Leonska-Duniec A, Wilk M, Filip
A, Cieszczyk P, et al. Genetics of muscle stiffness, muscle elasticity and
explosive strength. J Hum Kinet. 2020;74:143–59.
Karki R, Pandya D, Elston RC, Ferlini C. Defining, “mutation” and “polymorphism” in the era of personal genomics. BMC Med Genom. 2015;8:37.
Kostek M, Hubal MJ, Pescatello LS. The role of genetic variation in muscle
strength. Am J Lifestyle Med. 2011;5(2):156–70.
Pickering C, Kiely J. ACTN3: more than just a gene for speed. Front Physiol.
2017;8:1080.
Yang N, MacArthur DG, Gulbin JP, Hahn AG, Beggs AH, Easteal S, et al.
ACTN3 genotype is associated with human elite athletic performance.
Am J Hum Genet. 2003;73(3):627–31.
Harmon BT, Orkunoglu-Suer EF, Adham K, Larkin JS, Gordish-Dressman
H, Clarkson PM, et al. CCL2 and CCR2 variants are associated with skeletal
muscle strength and change in strength with resistance training. J Appl
Physiol. 2010;109(6):1779–85.
Iwao-Koizumi K, Ota T, Hayashida M, Yonetani Y, Nakata K, Kinoshita K,
et al. The ACTN3 gene is a potential biomarker for the risk of non-contact
sports injury in female athletes. J Mol Biomark Diagn. 2014;S6(002):1–7.
Gibbon A, Raleigh SM, Ribbans WJ, Posthumus M, Collins M, September
AV. Functional COL1A1 variants are associated with the risk of acute
musculoskeletal soft tissue injuries. J Orthop Res. 2020;38(10):2290–8.
Pruna R, Artells R, Ribas J, Montoro B, Cos F, Munoz C, et al. Single nucleotide polymorphisms associated with non-contact soft tissue injuries
in elite professional soccer players: influence on degree of injury and
recovery time. BMC Musculoskelet Disord. 2013;14:221.
Stastny P, Lehnert M, De Ste CM, Petr M, Svoboda Z, Maixnerova E, et al.
Effect of COL5A1, GDF5, and PPARA genes on a movement screen
and neuromuscular performance in adolescent team sport athletes. J
Strength Cond Res. 2019;33(8):2057–65.
John R, Prabhakar S, Dhillon MS, Anand A, Minhas G. Association of ACL
tears and single nucleotide polymorphisms in the collagen 12 A1 gene
in the Indian population: a preliminary case–control study. Muscles Ligaments Tendons J. 2016;6(2):253–7.

Page 13 of 14

29. O’Connell K, Knight H, Ficek K, Leonska-Duniec A, Maciejewska-Karlowska
A, Sawczuk M, et al. Interactions between collagen gene variants and risk
of anterior cruciate ligament rupture. Eur J Sport Sci. 2015;15(4):341–50.
30. Urano T, Shiraki M, Usui T, Sasaki N, Ouchi Y, Inoue S. Bone mass effects
of a Smad6 gene polymorphism in Japanese postmenopausal women. J
Bone Miner Metab. 2009;27(5):562–6.
31. Dimitriou R, Carr IM, West RM, Markham AF, Giannoudis PV. Genetic predisposition to fracture non-union: a case control study of a preliminary
single nucleotide polymorphisms analysis of the BMP pathway. BMC
Musculoskelet Disord. 2011;12:44.
32. Devlin RD, Du Z, Pereira RC, Kimble RB, Economides AN, Jorgetti V, et al.
Skeletal overexpression of noggin results in osteopenia and reduced
bone formation. Endocrinology. 2003;144(5):1972–8.
33. Sun S, Wang Y, Wu Y, Gao Y, Li Q, Abdulrahman AA, et al. Identification
of COL1A1 as an invasionrelated gene in malignant astrocytoma. Int J
Oncol. 2018;53(6):2542–54.
34. Laguette MJ, Abrahams Y, Prince S, Collins M. Sequence variants within
the 3’-UTR of the COL5A1 gene alters mRNA stability: implications for
musculoskeletal soft tissue injuries. Matrix Biol. 2011;30(5–6):338–45.
35. Hicks D, Farsani GT, Laval S, Collins J, Sarkozy A, Martoni E, et al. Mutations
in the collagen XII gene define a new form of extracellular matrix-related
myopathy. Hum Mol Genet. 2014;23(9):2353–63.
36. MacArthur DG, North KN. ACTN3: a genetic influence on muscle function
and athletic performance. Exerc Sport Sci Rev. 2007;35(1):30–4.
37. Bergman D, Halje M, Nordin M, Engstrom W. Insulin-like growth factor 2 in
development and disease: a mini-review. Gerontology. 2013;59(3):240–9.
38. Zhu S, Liu M, Bennett S, Wang Z, Pfleger KDG, Xu J. The molecular
structure and role of CCL2 (MCP-1) and C-C chemokine receptor CCR2 in
skeletal biology and diseases. J Cell Physiol. 2021;236(10):7211–22.
39. Litteri G, Carnevale D, D’Urso A, Cifelli G, Braghetta P, Damato A, et al.
Vascular smooth muscle Emilin-1 is a regulator of arteriolar myogenic response and blood pressure. Arterioscler Thromb Vasc Biol.
2012;32(9):2178–84.
40. Zacchigna L, Vecchione C, Notte A, Cordenonsi M, Dupont S, Maretto S,
et al. Emilin1 links TGF-beta maturation to blood pressure homeostasis.
Cell. 2006;124(5):929–42.
41. Lim T, Santiago C, Pareja-Galeano H, Iturriaga T, Sosa-Pedreschi A, Fuku N,
et al. Genetic variations associated with non-contact muscle injuries in
sport: a systematic review. Scand J Med Sci Sports. 2021;31(11):2014–32.
42. Choi M, Stottmann RW, Yang YP, Meyers EN, Klingensmith J. The bone
morphogenetic protein antagonist noggin regulates mammalian cardiac
morphogenesis. Circ Res. 2007;100(2):220–8.
43. Galvin KM, Donovan MJ, Lynch CA, Meyer RI, Paul RJ, Lorenz JN, et al. A
role for smad6 in development and homeostasis of the cardiovascular
system. Nat Genet. 2000;24(2):171–4.
44. Miyamoto-Mikami E, Miyamoto N, Kumagai H, Hirata K, Kikuchi N, Zempo
H, et al. COL5A1 rs12722 polymorphism is not associated with passive
muscle stiffness and sports-related muscle injury in Japanese athletes.
BMC Med Genet. 2019;20(1):192.
45. Zhao D, Zhang Q, Lu Q, Hong C, Luo T, Duan Q, et al. Correlations
between the genetic variations in the COL1A1, COL5A1, COL12A1, and
beta-fibrinogen genes and anterior cruciate ligament injury in Chinese
patients. J Athl Train. 2020;55(5):515–21.
46. Ficek K, Cieszczyk P, Kaczmarczyk M, Maciejewska-Karlowska A, Sawczuk
M, Cholewinski J, et al. Gene variants within the COL1A1 gene are associated with reduced anterior cruciate ligament injury in professional soccer
players. J Sci Med Sport. 2013;16(5):396–400.
47. Massidda M, Voisin S, Culigioni C, Piras F, Cugia P, Yan X, et al. ACTN3
R577X polymorphism is associated with the incidence and severity of injuries in professional football players. Clin J Sport Med.
2019;29(1):57–61.
48. Stepien-Slodkowska M, Ficek K, Eider J, Leonska-Duniec A, MaciejewskaKarlowska A, Sawczuk M, et al. The +1245g/t polymorphisms in the collagen type I alpha 1 (col1a1) gene in polish skiers with anterior cruciate
ligament injury. Biol Sport. 2013;30(1):57–60.
49. McCaskie CJ, Sim M, Newton RU, Hart NH. Lower-limb injury in elite
Australian football: a narrative review of kinanthropometric and physical
risk factors. Phys Ther Sport. 2021;52:69–80.

Jacob et al. Sports Medicine - Open

(2022) 8:126

50. Finch CF, Twomey DM, Fortington LV, Doyle TL, Elliott BC, Akram M, et al.
Preventing Australian football injuries with a targeted neuromuscular
control exercise programme: comparative injury rates from a training
intervention delivered in a clustered randomised controlled trial. Inj Prev.
2016;22(2):123–8.
51. Stares J, Dawson B, Peeling P, Heasman J, Rogalski B, Drew M, et al. Identifying high risk loading conditions for in-season injury in elite Australian
football players. J Sci Med Sport Sports Med Aust. 2018;21(1):46–51.
52. Jacob Y, Hart NH, Cochrane Wilke J, Spiteri T, Laws SM, Jones A, et al.
ACTN3 (R577X) genotype is associated with Australian football league
players. J Strength Cond Res. 2022;36(2):573–6.
53. Jacob Y, Anderton RS, Cochrane Wilkie JL, Rogalski B, Laws SM, Jones A,
et al. Association of genetic variances in ADRB1 and PPARGC1a with twokilometre running time-trial performance in Australian football league
players: a preliminary study. Sports. 2021;9(2):22.
54. Jacob Y, Chivers P, Anderton RS. Genetic predictors of match performance in sub-elite Australian football players: a pilot study. J Exerc Sci Fit.
2019;17(2):41–6.
55. Massidda M, Bachis V, Corrias L, Piras F, Scorcu M, Calò CM. Influence of
the COL5A1 rs12722 on musculoskeletal injuries in professional soccer
players. J Sports Med Phys Fitness. 2015;55(11):1348–53.
56. Collins M, Posthumus M. Type V collagen genotype and exercise-related
phenotype relationships: a novel hypothesis. Exerc Sport Sci Rev.
2011;39(4):191–8.
57. Kadler KE, Baldock C, Bella J, Boot-Handford RP. Collagens at a glance. J
Cell Sci. 2007;120(Pt 12):1955–8.
58. Guo R, Ji Z, Gao S, Aizezi A, Fan Y, Wang Z, et al. Association of COL5A1
gene polymorphisms and musculoskeletal soft tissue injuries: a
meta-analysis based on 21 observational studies. J Orthop Surg Res.
2022;17(1):129.
59. Pruna R, Ribas J, Montoro JB, Artells R. The impact of single nucleotide
polymorphisms on patterns of non-contact musculoskeletal soft tissue
injuries in a football player population according to ethnicity. Med Clin.
2015;144(3):105–10.
60. Del Coso J, Valero M, Salinero JJ, Lara B, Gallo-Salazar C, Areces F.
Optimum polygenic profile to resist exertional rhabdomyolysis during a
marathon. PLoS ONE. 2017;12(3): e0172965.
61. Posthumus M, September AV, Keegan M, O’Cuinneagain D, Van
der Merwe W, Schwellnus MP, et al. Genetic risk factors for anterior
cruciate ligament ruptures: COL1A1 gene variant. Br J Sports Med.
2009;43(5):352–6.
62. Khoschnau S, Melhus H, Jacobson A, Rahme H, Bengtsson H, Ribom
E, et al. Type I collagen alpha1 Sp1 polymorphism and the risk of
cruciate ligament ruptures or shoulder dislocations. Am J Sports Med.
2008;36(12):2432–6.
63. Clifford T, Ventress M, Allerton DM, Stansfield S, Tang JCY, Fraser WD, et al.
The effects of collagen peptides on muscle damage, inflammation and
bone turnover following exercise: a randomized, controlled trial. Amino
Acids. 2019;51(4):691–704.
64. Dar QA, Schott EM, Catheline SE, Maynard RD, Liu Z, Kamal F, et al. Daily
oral consumption of hydrolyzed type 1 collagen is chondroprotective
and anti-inflammatory in murine posttraumatic osteoarthritis. PLoS ONE.
2017;12(4): e0174705.
65. Ekstrand J, Torstveit MK. Stress fractures in elite male football players.
Scand J Med Sci Sports. 2012;22(3):341–6.
66. Fortington LV, Berry J, Buttifant D, Ullah S, Diamantopoulou K, Finch CF.
Shorter time to first injury in first year professional football players: a
cross-club comparison in the Australian Football League. J Sci Med Sport
Sports Med Aust. 2016;19(1):18–23.
67. Nose-Ogura S, Yoshino O, Dohi M, Kigawa M, Harada M, Hiraike O, et al.
Risk factors of stress fractures due to the female athlete triad: differences
in teens and twenties. Scand J Med Sci Sports. 2019;29(10):1501–10.
68. Del Coso J, Salinero JJ, Lara B, Gallo-Salazar C, Areces F, Herrero D, Puente
C. Polygenic profile and exercise-induced muscle damage by a competitive half-ironman. J Strength Cond Res. 2020;34(5):1400–8.
69. Hart NH, Nimphius S, Rantalainen T, Ireland A, Siafarikas A, Newton
RU. Mechanical basis of bone strength: influence of bone material,
bone structure and muscle action. J Musculoskelet Neuronal Interact.
2017;17(3):114–39.

Page 14 of 14

70. Hart NH, Newton RU, Tan J, Rantalainen T, Chivers P, Siafarikas A, Nimphius
S. Biological basis of bone strength: anatomy, physiology and measurement. J Musculoskelet Neuronal Interact. 2020;20(3):347–71.
71. Fortington LV, Hart NH. Models for understanding and preventing
fractures in sport. In: Robertson GAJ, Maffuli N, editors. Fractures in sport.
Champaign: Springer; 2020. p. 75–84.
72. Hart NH, Newton RU, Weber J, Spiteri T, Rantalainen T, Dobbin M, Chivers
P, Nimphius S. Functional basis of asymmetrical lower-body skeletal
morphology in professional Australian rules footballers. J Strength Cond
Res. 2020;34(3):791–9.
73. Maughan RJ, Burke LM, Dvorak J, Larson-Meyer DE, Peeling P, Phillips SM,
Rawson ES, Walsh NP, Garthe I, Geyer H, Meeusen R. IOC consensus statement: dietary supplements and the high-performance athlete. Int J Sport
Nutr Exerc Metab. 2018;28(2):104–25.
74. Fredericson M, Kussman A, Misra M, Barrack MT, De Souza MJ, Kraus E,
Koltun KJ, Williams NI, Joy E, Nattiv A. The male athlete triad: a consensus
statement from the female and male athlete triad coalition. Part II: diagnosis, treatment, and return-to-play. Clin J Sport Med. 2021;31(4):349–66.
75. Australian Football League: Australian Football Anti-Doping Code, Version
2021.1. https://www.afl.com.au/clubhelp/policies/member-protection-
and-integrity/anti-doping-code (2021). Accessed 15 Aug 2022.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

